Norman V Carroll

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10752006/publications.pdf

Version: 2024-02-01

42 papers

1,011 citations

567281 15 h-index 434195 31 g-index

42 all docs 42 docs citations

times ranked

42

1796 citing authors

#	Article	IF	CITATIONS
1	Economic burden of pediatric prescription opioid poisonings in the United States. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 16-26.	0.9	1
2	Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 137-146.	0.9	4
3	Should the United States government regulate prescription prices? A critical review. Research in Social and Administrative Pharmacy, 2020, 16, 717-723.	3.0	5
4	Economic burden of renal cell carcinoma among older adults in the targeted therapy era. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 356.e19-356.e28.	1.6	12
5	Risk Factors for Serious Prescription Opioid-Induced Respiratory Depression or Overdose: Comparison of Commercially Insured and Veterans Health Affairs Populations. Pain Medicine, 2018, 19, 79-96.	1.9	42
6	A Comparison of Pharmacy Dispensing Channel Use and Adherence to Specialty Drugs Among Medicare Part D Beneficiaries. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 317-326.	0.9	8
7	Cost-effectiveness of hepatitis C–positive donor kidney transplantation for hepatitis C–negative recipients with concomitant direct-acting antiviral therapy. American Journal of Transplantation, 2018, 18, 2496-2505.	4.7	50
8	The Medicaid Rebate: Changes in Oncology Drug Prices After the Affordable Care Act. Applied Health Economics and Health Policy, 2017, 15, 513-520.	2.1	4
9	Economic burden of refractory chronic spontaneous urticaria on Kuwait's health system. ClinicoEconomics and Outcomes Research, 2016, 8, 163.	1.9	9
10	Examination of the Link Between Medication Adherence and Use of Mail-Order Pharmacies in Chronic Disease States. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 1247-1259.	0.9	33
11	Effectiveness of a Pharmacistâ€Physician Teamâ€Based Collaboration to Improve Longâ€Term Blood Pressure Control at an Innerâ€City Safetyâ€Net Clinic. Pharmacotherapy, 2016, 36, 342-347.	2.6	34
12	Selfâ€reported financial burden of cancer care and its effect on physical and mental healthâ€related quality of life among US cancer survivors. Cancer, 2016, 122, 283-289.	4.1	275
13	Analysis of Costs to Dispense Prescriptions in Independently Owned, Closed-Door Long-Term Care Pharmacies. Journal of Managed Care Pharmacy, 2014, 20, 291-300.	2.2	1
14	The Economic Burden of Opioid-Related Poisoning in the United States. Pain Medicine, 2013, 14, 1534-1547.	1.9	92
15	Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective: The ISPOR Drug Cost Task Force Report—Part III. Value in Health, 2010, 13, 14-17.	0.3	21
16	Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Reportâ€"Part I. Value in Health, 2010, 13, 3-7.	0.3	81
17	Evaluation of Health Plan Member Use of an Online Prescription Drug Price Comparison Tool. Journal of Managed Care Pharmacy, 2010, 16, 680-692.	2.2	3
18	Fall-Related Hospitalization and Facility Costs Among Residents of Institutions Providing Long-Term Care. Gerontologist, The, 2008, 48, 213-222.	3.9	27

#	Article	IF	Citations
19	Estimating the Impact of Medicare Part D on the Profitability of Independent Community Pharmacies. Journal of Managed Care Pharmacy, 2008, 14, 768-779.	2.2	18
20	Examining the Rift Between the Pharmaceutical Industry and the Pharmacy Profession: A Channels of Distribution Approach. Journal of Pharmaceutical Marketing and Management, 2007, 18, 21-33.	0.1	2
21	Pharmaceutical Patient Assistance Programs: Don't Look a Gift Horse in the Mouth or There's No Such Thing as a Free Lunch. Journal of Managed Care Pharmacy, 2007, 13, 614-616.	2.2	8
22	Evaluation of an automated system for prior authorization: a COX-2 inhibitor example. American Journal of Managed Care, 2006, 12, 501-8.	1.1	5
23	The Cost of Falls Among the Community-Dwelling Elderly. Journal of Managed Care Pharmacy, 2005, 11, 307-316.	2.2	128
24	Do Community Pharmacists Influence Prescribing?. Journal of the American Pharmacists Association: JAPhA, 2003, 43, 612-621.	1.5	20
25	How effectively do managed care organizations influence prescribing and dispensing decisions?. American Journal of Managed Care, 2002, 8, 1041-54.	1.1	16
26	Therapeutic interchange in community pharmacies in Virginia. American Journal of Health-System Pharmacy, 2000, 57, 882-894.	1.0	8
27	Formularies and therapeutic interchange: The health care setting makes a difference. American Journal of Health-System Pharmacy, 1999, 56, 467-472.	1.0	10
28	Elderly Consumers' Views of Community and Mail-Order Pharmacies. Journal of Pharmaceutical Marketing and Management, 1992, 6, 3-20.	0.1	3
29	Risks, Benefits, and Generic Substitution. Journal of Consumer Affairs, 1991, 25, 110-121.	2.3	7
30	Effect of the prospective-pricing system on drug use in Pennsylvania long-term-care facilities. American Journal of Health-System Pharmacy, 1990, 47, 2251-2254.	1.0	5
31	Influence of patients' of age, sex, and race on prescription drug use among Georgia Medicaid recipients. American Journal of Health-System Pharmacy, 1989, 46, 287-290.	1.0	9
32	Consumer Attitudes and Actions Toward Generic Drugs. Journal of Pharmaceutical Marketing and Management, 1988, 2, 87-99.	0.1	7
33	Consumer Perceptions of Prescription Prices. Journal of Pharmaceutical Marketing and Management, 1988, 3, 111-116.	0.1	0
34	A Comparative Study of Current Medicaid Prescription Reimbursement (MACtEAC) with Prescription Reimbursement Based on a Competitive Market. Journal of Pharmaceutical Marketing and Management, 1988, 3, 37-46.	0.1	1
35	Consumer Attitudes and Actions Toward Generic Drugs. Journal of Pharmaceutical Marketing and Management, 1988, 2, 87-99.	0.1	4
36	Consumer Perceptions of Prescription Prices. Journal of Pharmaceutical Marketing and Management, 1988, 3, 111-116.	0.1	0

#	Article	IF	CITATIONS
37	Demographic and Prescription Patronage Motive Differences Among Segments in the Community Pharmacy Market. Journal of Pharmaceutical Marketing and Management, 1987, 1, 19-33.	0.1	20
38	Effect of the prospective-pricing system on drug use in Medicare patients in Georgia long-term-care facilities. American Journal of Health-System Pharmacy, 1987, 44, 1406-1408.	1.0	0
39	Demographic and Prescription Patronage Motive Differences Among Segments in the Community Pharmacy Market. Journal of Pharmaceutical Marketing and Management, 1987, 1, 19-33.	0.1	5
40	Professionals in Bureaucracies. Journal of Pharmaceutical Marketing and Management, 1986, 1, 27-39.	0.1	6
41	Pharmacists' Perceptions of Consumer Demand for Patient-Oriented Pharmacy Services. Drug Intelligence & Clinical Pharmacy, 1984, 18, 640-644.	0.4	6
42	The Relationship between Patient Variables and Frequency of Pharmacist Counseling. Drug Intelligence & Clinical Pharmacy, 1983, 17, 648-652.	0.4	21